Literature DB >> 2409383

Role of cyclic-GMP in relaxations of vascular smooth muscle.

F Murad, R M Rapoport, R Fiscus.   

Abstract

Relaxation of rat aorta segments with sodium nitroprusside and endothelium-dependent vasodilators, such as acetylcholine, histamine, A23187, ATP, thrombin, and trypsin, is associated with cyclic-GMP (cGMP) accumulation in a concentration- and time-dependent fashion. With rat aorta segments, these agents also increase cyclic GMP-dependent protein-kinase activity and alter the incorporation of 32P into numerous smooth-muscle proteins. Identical patterns of protein phosphorylation were observed with both classes of relaxants on two-dimensional gel electrophoresis and autoradiography. The effects of nitroprusside were observed with or without the endothelium present. In contrast, the effects of the endothelium-dependent agents on all of these parameters (cGMP, cGMP-dependent protein kinase and protein phosphorylation) required the integrity of the endothelium. Various inhibitors of phospholipase and lypoxygenase prevented the effects of the endothelium-dependent agents, suggesting that a metabolite of arachidonic acid is the endothelium-relaxant factor and responsible for guanylate-cyclase activation. A smooth-muscle protein with decreased 32P incorporation after treatment with either class of relaxants has been identified as myosin light chain. A model is presented suggesting that the effects of endothelium-dependent vasodilators and directly acting nitrovasodilators converge at the level of guanylate-cyclase activation and cGMP accumulation, which explains the common biochemical and physiological effects on smooth muscle of these two classes of vasodilators.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2409383

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  14 in total

1.  Inhibition of vascular smooth muscle relaxation by LY83583.

Authors:  E Malta; P S Macdonald; G J Dusting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-04       Impact factor: 3.000

2.  The influence of endothelium on the action of PGF2 alpha and some dihydropyridine-type calcium antagonists in porcine basilar arteries.

Authors:  G Kojda; W Klaus; G Werner; U Fricke
Journal:  Basic Res Cardiol       Date:  1991 May-Jun       Impact factor: 17.165

Review 3.  Atrial natriuretic factor. A newly discovered hormone with significant clinical implications.

Authors:  G Thibault; R Garcia; J Gutkowska; J Genest; M Cantin
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

4.  Interaction of atriopeptin III and vasopressin on calcium kinetics and contraction of aortic smooth muscle cells.

Authors:  H Meyer-Lehnert; C Caramelo; P Tsai; R W Schrier
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

5.  Direct chronotropic effects of atrial and C-type natriuretic peptides in anaesthetized dogs.

Authors:  P Beaulieu; R Cardinal; A De Léan; C Lambert
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

6.  Pharmacological and histological examinations of regional differences of guinea-pig lung: a role of pleural surface smooth muscle in lung strip contraction.

Authors:  W S Wong; S L Bloomquist; A M Bendele; J H Fleisch
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

7.  Nitric oxide (EDRF) enhances the vasorelaxing effect of nitrendipine in various isolated arteries.

Authors:  J Günther; S Dhein; R Rösen; W Klaus; U Fricke
Journal:  Basic Res Cardiol       Date:  1992 Sep-Oct       Impact factor: 17.165

8.  Cyclic GMP-dependent protein kinase stimulates the plasmalemmal Ca2+ pump of smooth muscle via phosphorylation of phosphatidylinositol.

Authors:  M Vrolix; L Raeymaekers; F Wuytack; F Hofmann; R Casteels
Journal:  Biochem J       Date:  1988-11-01       Impact factor: 3.857

Review 9.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

10.  Potential Benefits of Peroxynitrite.

Authors:  Bobby D Nossaman; Philip J Kadowitz
Journal:  Open Pharmacol J       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.